Evaluation of Lysine-Specific Demethylase 1
NCT01702688 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2017-07-12
Summary
Thank you for your interest in our Blood Pressure Research Study. The American Heart Association is sponsoring us to investigate why patients develop high blood pressure, atherosclerosis (hardening of the arteries), and heart disease. There are two parts of our research program. The first part is a screening visit. At this visit you will be given a brief physical exam and will be asked questions concerning your medical history. During the same visit you will have your blood drawn for routine screening and genetic testing. You will also be asked to collect a urine sample for routine screening.
If the doctor finds that you are a healthy candidate you will be invited to participate in the second part of the study. During Phase II, we will perform physiological tests after you are placed on a low salt diet and again after you are placed on a higher salt diet. If you are on blood pressure medication, it may be necessary to discontinue taking your present medication for up to three months before beginning the study. Patients discontinuing their current blood pressure medication may be placed on a different blood pressure medication during this 'washout' period if necessary to maintain blood pressure at pre-study levels.
Once your blood pressure medications are discontinued, you will be closely monitored. If you do not own a home blood pressure monitor, we will provide one for you to use during the study so that you can keep a daily record of your blood pressure readings. We will ask you to call us every three days to report your blood pressure readings. After you have stopped taking your medication, dietitians at the hospital will make you low salt meals to eat at home for about seven days. On the last day of the low salt diet, you will be asked to begin a 24-hour urine collection that you will bring with you when you are admitted to the hospital that evening. That morning, you will be required to come to the Center for Clinical Investigations (CCI) at Brigham and Women's Hospital for a one-hour test to check if your body is in the correct salt balance.
You will return that evening to the CCI where you will be admitted for your study that will occur the next morning. On the morning of your low salt study, we will collect some blood samples. We will also take ultrasound pictures of your heart to see how salt and hormones affect the way your heart and blood vessels functions. These tests will last approximately 5 hours and you will be discharged around 2:00 PM. For the next 5-7 days, you will be placed on a liberal salt diet. During this diet period, you will eat all your own food, but we will give you some supplements to add to your meals. After 5-7 days on your liberal salt diet, on the morning of your second admission to the hospital, you will be asked to begin a final 24-hour urine collection. That morning, you will again be required to come to the CCI for a blood test, and you will return later that evening to the inpatient CCI where you will be admitted for your final overnight study. The same study that was done for the low salt diet will be repeated for the liberal salt study. You will be discharged at around 2:00 p.m. These studies will help to determine if you are salt-sensitive. In addition, we hope to learn more about the hormones that regulate your blood pressure and the genes responsible for regulating those hormones.
You will be placed back on your initial blood pressure medication (if you are on any) and returned to your regular physician for care. We can also provide clinically relevant information to you.
Conditions
Interventions
- DRUG
-
Para-aminohippuric Acid
Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated "PAH".
- DRUG
-
Angiotensin II
Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Bindu Chamarthi, MD · Brigham and Women's Hospital
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-07-31
Countries
- United States
Study Locations
More Related Trials
-
Genetic Mechanisms in Human Hypertension
NCT01456208 ·Status: TERMINATED
-
A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure)
NCT03590860 ·Status: TERMINATED ·Phase: PHASE1
-
Genetic Architecture of Natriuretic Peptides and Blood Pressure Response
NCT07118592 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Amino Acids in Urine, Diet, and Blood Pressure: International Population Study
NCT00006406 ·Status: COMPLETED
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
NCT06482853 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Renal Metabolism in Salt-sensitive Human Blood Pressure
NCT05369416 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Targeting Endoplasmic Reticulum Stress in Human Hypertension
NCT06025630 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure
NCT00925470 ·Status: COMPLETED
-
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
NCT01658657 ·Status: COMPLETED ·Phase: NA
-
National Survey on Hypertension at Hospital
NCT00695266 ·Status: COMPLETED
-
Angiotensin 1-7 in Obesity Hypertension
NCT03604289 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
The Natriuretic Peptide System in African-Americans.
NCT02730780 ·Status: COMPLETED ·Phase: NA
-
Prognostic Value of Plasma Biomarkers Among Patients With Hypertension
NCT04107584 ·Status: UNKNOWN
-
Renal Denervation for Complicated Hypertension
NCT01865253 ·Status: TERMINATED ·Phase: PHASE4
-
Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans
NCT04506645 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness of the DASH Diet at Reducing High Blood Pressure
NCT00123006 ·Status: COMPLETED ·Phase: NA
-
Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
NCT02591173 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
NCT01320722 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study
NCT05352633 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Soybean Peptides Product on Regulation of Blood Pressure Effect in Humans
NCT03828955 ·Status: COMPLETED ·Phase: NA
-
Systolic Blood Pressure Intervention Trial
NCT01206062 ·Status: COMPLETED ·Phase: NA
-
Dietary Salt Intake and Vascular Function
NCT00590512 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
NCT00689819 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension
NCT00710372 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Denervation for Uncontrolled Hypertension
NCT02016573 ·Status: WITHDRAWN ·Phase: NA